Humacyte, Inc.
HUMA
$1.29
$0.032.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 753.00K | 301.00K | 517.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 753.00K | 301.00K | 517.00K | -- | -- |
| Cost of Revenue | 17.53M | 22.22M | 15.57M | 20.66M | 22.93M |
| Gross Profit | -16.78M | -21.92M | -15.05M | -20.66M | -22.93M |
| SG&A Expenses | 7.61M | 7.81M | 8.14M | 7.43M | 7.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.14M | 30.03M | 23.70M | 28.09M | 30.23M |
| Operating Income | -24.39M | -29.73M | -23.18M | -28.09M | -30.23M |
| Income Before Tax | -17.51M | -37.66M | 39.14M | -20.94M | -39.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.51M | -37.66M | 39.14M | -20.94M | -39.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.51M | -37.66M | 39.14M | -20.94M | -39.20M |
| EBIT | -24.39M | -29.73M | -23.18M | -28.09M | -30.23M |
| EBITDA | -22.53M | -27.87M | -21.35M | -26.28M | -28.42M |
| EPS Basic | -0.11 | -0.24 | 0.30 | -0.16 | -0.33 |
| Normalized Basic EPS | -0.09 | -0.13 | -0.05 | -0.13 | -0.16 |
| EPS Diluted | -0.11 | -0.24 | 0.29 | -0.16 | -0.33 |
| Normalized Diluted EPS | -0.09 | -0.13 | -0.05 | -0.13 | -0.16 |
| Average Basic Shares Outstanding | 158.31M | 155.44M | 131.63M | 126.98M | 119.41M |
| Average Diluted Shares Outstanding | 158.31M | 155.44M | 131.89M | 126.98M | 119.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |